Koers TrovaGene Inc Nasdaq
Aandelen
US8972383090
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 242K 227K | Omzet 2025 * | 66,67K 62,54K | Marktkapitalisatie | 195 mln. 183 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -46 mln. -43,15 mln. | Nettowinst (verlies) 2025 * | -57 mln. -53,47 mln. | EV/omzet 2024 * | 804 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 2.924 x |
K/w-verhouding 2024 * |
-4,47
x | K/w-verhouding 2025 * |
-4,14
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 92,32% |
Recentste transcriptie over TrovaGene Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Mark Erlander
CEO | Chief Executive Officer | 64 | 04-03-13 |
James Levine
DFI | Director of Finance/CFO | 53 | 12-07-21 |
Tod Smeal
CTO | Chief Tech/Sci/R&D Officer | 59 | 11-01-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
James Armitage
BRD | Director/Board Member | 77 | 22-04-20 |
Gary Pace
BRD | Director/Board Member | 76 | 22-04-20 |
Mark Erlander
CEO | Chief Executive Officer | 64 | 04-03-13 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+0,17% | 42,19 mld. | |
+10,92% | 42,24 mld. | |
+44,30% | 40,15 mld. | |
-6,20% | 28,31 mld. | |
+5,23% | 24,63 mld. | |
-24,79% | 18,2 mld. | |
+26,69% | 12,01 mld. | |
-3,13% | 11,76 mld. | |
+6,57% | 10,4 mld. |